Natasha holds first-class honors in Biological Sciences from the University of Leeds. She completed an industrial placement with Johnson & Johnson during her degree, working in medical device regulatory affairs. After graduating from university, she worked for regulatory consultancy firm JensonR+ across medicines, medical devices, food supplements, and cosmetics. In 2022, she moved to London to work for the UK consumer healthcare association. She joined Medtech Insight in November 2023 and reports on the latest commercial and policy developments in diagnostics and AI digital technologies, covering therapeutic areas such as cancer and cardiology.
Latest from Natasha Barrow
J&J's EMEA head of digital solutions, Julia Fishman, talks about the major hurdles in scaling digital innovation, tips for clinical adoption and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.
The KINCISE 2 Surgical Automated System aims to “reduce the physical burden on surgeons compared to manual impaction in primary and revision hip and revision knee replacement procedures,” said J&J MedTech.
In this week's Digital Health Roundup, MedTech Insight's Shubham Singh explores how Ketryx's launch of validated AI agents could reshape compliance automation in medtech. Marion Webb highlights news from BCI makers Synchron, Axoft and Subsense. Elizabeth Orr discusses AI advances at the FDA.
Guardant Health’s methylation-based blood test – Shield MCD – showed a specificity of 98.6% and sensitivity of 75% across eight cancer types in its clinical validation data presented at ASCO.
A UK research team has used artificial intelligence to find new treatments for cancer using existing US Food and Drug Administration-approved medicines that are not normally not used for the disease.
Clairity’s "first-in-class" mammography-based AI screening tool, Clairity Breast, provides "equitable risk assessments," expanding access to lifesaving early detection for breast cancer, said company founder Connie Lehman.